Cost-effectiveness Analysis of Levofloxacin and Cefoxitin in the Treatment of Adult Non-severe Communi-ty-acquired Pneumonia
10.6039/j.issn.1001-0408.2015.29.01
- VernacularTitle:左氧氟沙星与头孢西丁治疗成人非重症社区获得性肺炎的成本-效果分析
- Author:
Sijing LIU
- Publication Type:Journal Article
- Keywords:
Levofloxacin;
Cefoxitin;
Adult non-severe community-acquired pneumonia;
Cost-effectiveness analysis
- From:
China Pharmacy
2015;(29):4033-4034,4035
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate and compare cost-effectiveness of levofloxacin and cefoxitin in the treatment of adult non-severe community-acquired pneumonia(CAP). METHODS:71 cases of adult non-severe CAP were selected and divided into levofloxacin group (group A,33 cases) and cefoxitin group (group B,38 cases). Gronp A received Mesylate levofloxacin injec-tien 200 ml inotraveously,once a day;group B received Cefoxitin for injection 2.0 g intravenously,3 times a day,for 8 days. Clinical efficacy,excellence time and ADR of 2 groups were observed,and cost-effectiveness analysis was conducted. RESULTS:The total effective rate of group A and group B were 87.88% and 65.79%,and excellence time(5.53±2.56)d and(3.87±3.03)d, with statistical significance(P<0.05);there was no statistical significance in the incidence of ADR between 2 groups(χ2=0.47, P>0.05). The total costs were 6 748.93 yuan and 8 110.34 yuan;the cost-effectiveness ratios were 76.80 and 123.28;incremental cost-effectiveness ratio was -61.63%. Results of sensitivity analysis matched results of cost-effectiveness analysis. CONCLU-SIONS:Levofloxacin save more and is economical in the treatment of adult non-severe CAP.
